Myth-buster
In a 24-week trial, vitamin E failed to budge the NAFLD fibrosis score in non-diabetic MASLD patients — a -0.12 point change that didn't reach statistical significance.
This open-label trial contradicts the common notion that vitamin E helps liver scarring in fatty liver disease, but because the study was small (136 people), unblinded, and short-term, the debate is far from settled.
The study compared vitamin E and a drug (saroglitazar) against lifestyle changes alone for non-diabetic people with metabolic liver disease. After 24 weeks, none of the treatments meaningfully improved liver fibrosis scores or stiffness—though the authors note a trend toward reduced liver stiffness with saroglitazar. The null result means that, at least in this short trial, vitamin E did not outperform standard lifestyle advice for this specific liver scarring measure.
Where this fits in the evidence
This is among the first studies we've indexed on Vitamin E for Reduced NAFLD Fibrosis Score — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- n = 136
- 2026-05-16
- The Indian journal of medical research
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.